Chronic inflammation underlies many age-related diseases—cardiovascular disease, metabolic dysfunction, neurodegenerative conditions, and autoimmune disorders. While conventional anti-inflammatory strategies (NSAIDs, corticosteroids, lifestyle modification) address symptoms, peptides offer a mechanistically distinct advantage: they work through receptor-specific signaling pathways that modulate inflammation at the cellular and systemic level.
Unlike broad-spectrum supplements such as curcumin or omega-3s, peptides bind to specific receptors on immune cells, adipocytes, and endothelial tissues to trigger coordinated anti-inflammatory cascades. They simultaneously reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) while increasing anti-inflammatory markers (adiponectin, IL-10). This selectivity translates to more consistent, measurable effects across multiple inflammatory pathways—backed by human randomized controlled trials and meta-analyses rather than in vitro studies alone.
Peptides also bypass first-pass hepatic metabolism when administered via injection, achieving bioavailability and tissue penetration that oral supplements cannot match.
What It Is
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are synthetic analogs of the glucagon-like peptide-1 hormone. While marketed primarily for glucose control and weight loss, GLP-1 agonists function as potent anti-inflammatory agents through mechanisms including immune cell modulation, adipose tissue remodeling, and gut barrier integrity.
Evidence Tier: 4
GLP-1 agonists have the strongest evidence base for anti-inflammation among peptides, grounded in a meta-analysis of 52 randomized controlled trials involving 4,734 participants.
Key Findings
- Meta-analysis (52 RCTs, n=4,734): GLP-1 receptor agonists reduced C-reactive protein (CRP) by standardized mean difference (SMD) -0.63, TNF-α by SMD -0.92, IL-6 by SMD -0.76, IL-1β by SMD -3.89, and leptin by SMD -0.67, with simultaneous increases in the anti-inflammatory adipokine adiponectin (SMD 0.69).
- Observational study (n=255 type 2 diabetes patients): GLP-1 agonist treatment decreased adhesion molecules ICAM-1 and VCAM-1, reduced IL-6, TNF-α, and IL-12 protein levels, increased IL-10, and reduced carotid intima-media thickness—a surrogate marker of atherosclerosis progression.
Mechanism
GLP-1 agonists reduce systemic inflammation by suppressing monocyte activation, shifting macrophage polarization toward anti-inflammatory M2 phenotypes, and promoting regulatory T-cell expansion. They also reduce endotoxemia by restoring intestinal barrier function, thereby decreasing lipopolysaccharide translocation.
Dosing & Cost
- Dosing: 100–300 mcg once or twice daily (injection)
- Cost: $40–$120/month
- Clinical formulations (semaglutide, liraglutide, dulaglutide) are significantly more expensive; research-grade peptides typically fall in this range
Best For
Individuals with metabolic syndrome, type 2 diabetes, obesity, or cardiovascular disease who seek proven multi-pathway anti-inflammatory effects backed by large-scale human evidence.
What It Is
Tirzepatide is a dual GLP-1/GIP receptor agonist—the first-in-class peptide targeting both receptors simultaneously. This dual mechanism amplifies anti-inflammatory signaling beyond GLP-1 monotherapy, with particularly robust effects on visceral adiposity and hepatic inflammation.
Evidence Tier: 4
Tirzepatide demonstrates the most potent anti-inflammatory effects among injectable peptides in short-term human trials, though evidence remains limited to studies ≤52 weeks duration.
Key Findings
- Meta-analysis (6 RCTs): Tirzepatide reduced high-sensitivity CRP (hsCRP) by 32.9% (95% CI: -33.6 to -32.2) versus placebo; IL-6 reduced by 17.8% (95% CI: -24.3 to -11.3).
- SUMMIT RCT (n=731, heart failure with preserved ejection fraction): Tirzepatide reduced C-reactive protein by 37.2% (95% CI: -45.7 to -27.3) at 52 weeks, accompanied by improvements in diastolic function and exercise capacity.
Mechanism
GIP receptor agonism amplifies the anti-inflammatory benefits of GLP-1 signaling by additionally suppressing hepatic inflammation, reducing hepatic fat accumulation, and modulating intestinal immune tolerance. This dual pathway approach produces synergistic cytokine reductions.
Dosing & Cost
- Dosing: 2.5 mg starting dose, titrated to 5 mg, 10 mg, or 15 mg once weekly (injection)
- Cost: $150–$1,300/month (clinical-grade; research-grade sources typically $150–$400)
Best For
Individuals with obesity, nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction seeking maximized dual-pathway anti-inflammatory effects. Superior to GLP-1 monotherapy for reducing liver inflammation and systemic inflammatory burden.
What It Is
Dulaglutide is a GLP-1 receptor agonist structurally distinct from other GLP-1 analogs, with an extended half-life permitting once-weekly dosing. Clinically validated in multiple RCTs for anti-inflammatory efficacy.
Evidence Tier: 4
Dulaglutide has robust evidence from multiple human RCTs demonstrating consistent reductions in inflammatory biomarkers across type 2 diabetes and metabolic populations.
Key Findings
- 12-week RCT (n=60, type 2 diabetes): Dulaglutide monotherapy reduced TNF-α significantly (p<0.05), with additional 8-PGF2α reduction (oxidative stress marker).
- 12-week RCT (n=60, dulaglutide + probiotics): TNF-α reduction reached 43.6% (vs. 33.3% in dulaglutide alone; p<0.001), demonstrating potential synergy with microbiome-targeted interventions.
Mechanism
Identical to GLP-1 agonists—receptor-mediated immune modulation, intestinal barrier restoration, and adipose tissue remodeling.
Dosing & Cost
- Dosing: 0.75 mg–4.5 mg once weekly (injection)
- Cost: $850–$1,000/month (clinical formulation)
Best For
Individuals prioritizing once-weekly dosing convenience and those with type 2 diabetes or prediabetes seeking evidence-based anti-inflammatory peptide therapy.
Tier 3 peptides demonstrate consistent anti-inflammatory effects in human studies but lack the breadth of large-scale RCT replication (n>500) or meta-analytic confirmation present in Tier 4 compounds.
What It Is
Thymosin alpha-1 is an endogenous immune-modulating peptide secreted by thymic epithelial cells. It enhances T-cell maturation, shifts immune responses toward Th1 phenotypes, and reduces pro-inflammatory cytokine production in acute inflammatory states (sepsis, severe infection).
Evidence Tier: 3
Strong mechanistic and biomarker evidence, but clinical mortality benefit remains unproven. Most relevant for acute inflammatory contexts.
Key Findings
- Sepsis meta-analysis (n=915, combination therapy): Ulinastatin + thymosin alpha-1 reduced TNF-α by 73.86 ng/L (95% CI -91.00 to -56.73) and IL-6 by 55.04 ng/L (95% CI -61.22 to -48.85) versus control, with 28-day mortality reduction (RR 0.67, 95% CI 0.57–0.80). Note: combination therapy benefit, not thymosin alpha-1 alone.
- Severe acute pancreatitis meta-analysis (n=706): Lower-dose thymosin alpha-1 significantly reduced CRP by 30.12 mg/L (95% CI -35.75 to -24.49), increased CD4+ T cells by 4.53%, and improved CD4+/CD8+ ratio by 0.42.
Mechanism
Thymosin alpha-1 enhances T-cell receptor signaling, promotes thymic T-cell selection, and shifts dendritic cell cytokine profiles toward IL-12 (Th1 bias) while reducing IL-10-dependent immune tolerance in acute inflammation contexts.
Dosing & Cost
- Dosing: 1.6 mg twice weekly (injection)
- Cost: $60–$200/month
Best For
Acute inflammatory states, post-surgical recovery, severe infections, or individuals with demonstrable T-cell immune deficiency. Less relevant for chronic low-grade inflammation.
What It Is
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that increases endogenous growth hormone (GH) secretion. GH itself exerts anti-inflammatory effects through modulation of immune cell differentiation and inflammatory adipokine production. FDA-approved for HIV-associated lipodystrophy.
Evidence Tier: 3
Specific anti-inflammatory efficacy demonstrated in HIV populations with NAFLD, but broader applicability and effect sizes remain modest.
Key Findings
- HIV + NAFLD RCT (n=61): Tesamorelin decreased 13 circulating immune proteins including chemokines (CCL3, CCL4, CCL13, IL-8) and cytokines (IL-10, CSF-1) versus placebo.
- Mechanistic correlations: Plasma VEGF-A and CSF-1 reductions correlated with improved NAFLD activity score; TGFB1 and CSF-1 reductions associated with reduced fibrosis-related gene expression.
Mechanism
GH-mediated suppression of TNF-α and IL-6 production by immune cells; enhanced adiponectin secretion; and reduced hepatic inflammatory cytokine signaling.
Dosing & Cost
- Dosing: 2 mg once daily (injection)
- Cost: $80–$400/month
Best For
HIV-positive individuals with NAFLD or lipodystrophy, or those with growth hormone deficiency seeking dual anti-inflammatory and metabolic benefits.
What It Is
ARA-290 is a synthetic erythropoietin-derived peptide that activates the innate immune-modulating receptor (IIMR), distinct from erythropoietin-stimulating agent mechanisms. It suppresses pro-inflammatory macrophage responses while preserving anti-infection immunity.
Evidence Tier: 3
Emerging human evidence with promising mechanistic rationale, but limited to 2–3 small RCTs without independent large-scale replication.
Key Findings
- Type 2 diabetes RCT (n=unspecified, phase 2): ARA-290 4 mg daily for 28 days improved HbA1c, lipid profiles, and neuropathic pain (PainDetect questionnaire improvement; increased corneal nerve fiber density) versus placebo.
- Aging rat RCT (n=48, 15-month): Chronic ARA-290 treatment significantly reduced cardiac inflammatory markers and attenuated age-associated heart function decline, improving frailty index at 33 months of age.
Mechanism
IIMR signaling suppresses NF-κB-mediated pro-inflammatory transcription while upregulating anti-inflammatory pathways via JAK-STAT signaling in macrophages and innate lymphoid cells.
Dosing & Cost
- Dosing: 4 mg once daily (injection)
- Cost: $180–$480/month
Best For
Diabetic neuropathy, age-related inflammatory decline, or those seeking immune-modulating anti-inflammatory effects without immunosuppression.
What It Is
Cerebrolysin is a standardized porcine brain peptide and amino acid extract with neuroprotective and anti-inflammatory properties. Mechanistically, it reduces neuroinflammatory cytokine signaling while promoting neuronal survival pathways.
Evidence Tier: 3
Moderate evidence from human RCTs in neurological conditions and consistent animal efficacy, but limited to small sample sizes and heterogeneous endpoints.
Key Findings
- Vascular dementia RCT (n=242, 24 weeks): Cerebrolysin administration improved ADAS-cog+ score by 10.6 points versus 4.4 in placebo (p<0.0001), with concurrent reductions in neuroinflammatory markers.
- Rat stroke models (ischemia/reperfusion): Cerebrolysin reduced pro-inflammatory cytokines TNF-α, IL-1β, and IL-6; decreased NF-κB expression; increased anti-inflammatory markers; reduced infarct volume; and improved long-term functional recovery.
Mechanism
Peptide-mediated suppression of microglia activation and pro-inflammatory cytokine release; enhanced neuronal neurotrophic factor signaling; and reduced blood-brain barrier disruption.
Dosing & Cost
- Dosing: 5–30 mL (215–1,290 mg peptide fraction) once daily for clinical courses; 3–5× per week for off-label cognitive use (injection)
- Cost: $80–$400/month
Best For
Neurological conditions (stroke recovery, vascular dementia, post-COVID cognitive dysfunction) where neuroinflammation contributes to pathology.
What It Is
Exenatide is a synthetic GLP-1 receptor agonist derived from Gila monster venom. Once-weekly formulation (Bydureon) provides sustained GLP-1 signaling with comparable anti-inflammatory efficacy to modern GLP-1 agents.
Evidence Tier: 3
Multiple RCTs demonstrate anti-inflammatory effects, but evidence is limited by small sample sizes, short durations, and inconsistent measurement of inflammatory endpoints across trials.
Key Findings
- EXSCEL RCT (n=3,973): Once-weekly exenatide reduced Alzheimer's disease-associated inflammatory proteins including ficolin-2 (Cohen's d -0.019), PAI-1 (Cohen's d -0.033), and sVCAM-1 (Cohen's d 0.035) versus placebo over 1 year.
- Alcohol use disorder study (n=23 exenatide-treated): IL-6 reduced from 1.56 pg/mL (vs. 0.62 in controls), hsCRP from 3.30 mg/L (vs. 1.34 in controls), and FGF-21 from 1,794.97 pg/mL (vs. 306.11 in controls) with treatment.
Mechanism
Identical GLP-1 agonist mechanisms; slower clearance permits once-weekly dosing and sustained receptor activation.
Dosing & Cost
- Dosing: 5 mcg twice daily (injection)
- Cost: $650–$900/month (clinical formulation)
Best For
Those seeking twice-daily GLP-1 agonist therapy with long clinical safety record; less convenient dosing than modern once-weekly alternatives.
What It Is
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activation amplifies hepatic lipid mobilization and metabolic inflammation reduction beyond dual GLP-1/GIP agonism.
Evidence Tier: 3
Promising animal models and emerging human metabolic data, but human RCT outcome data remain limited; primarily observational and